- Home
- DARE vs NXTC Comparison
DARE vs NXTC Comparison
Compare DARE & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DARE
- NXTC
- Stock Information
- Founded
- DARE 2015
- NXTC 2015
- Country
- DARE United States
- NXTC United States
- Employees
- DARE N/A
- NXTC N/A
- Industry
- DARE Biotechnology: Pharmaceutical Preparations
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- DARE Health Care
- NXTC Health Care
- Exchange
- DARE Nasdaq
- NXTC Nasdaq
- Market Cap
- DARE 28.6M
- NXTC 24.6M
- IPO Year
- DARE N/A
- NXTC 2019
- Fundamental
- Price
- DARE $1.91
- NXTC $8.50
- Analyst Decision
- DARE Strong Buy
- NXTC Strong Buy
- Analyst Count
- DARE 2
- NXTC 3
- Target Price
- DARE $10.00
- NXTC $23.00
- AVG Volume (30 Days)
- DARE 173.3K
- NXTC 85.9K
- Earning Date
- DARE 11-13-2025
- NXTC 11-05-2025
- Dividend Yield
- DARE N/A
- NXTC N/A
- EPS Growth
- DARE N/A
- NXTC N/A
- EPS
- DARE N/A
- NXTC N/A
- Revenue
- DARE N/A
- NXTC N/A
- Revenue This Year
- DARE $5,401.89
- NXTC N/A
- Revenue Next Year
- DARE $6,257.18
- NXTC N/A
- P/E Ratio
- DARE N/A
- NXTC N/A
- Revenue Growth
- DARE N/A
- NXTC N/A
- 52 Week Low
- DARE $1.76
- NXTC $2.69
- 52 Week High
- DARE $9.19
- NXTC $19.20
- Technical
- Relative Strength Index (RSI)
- DARE 43.71
- NXTC 44.66
- Support Level
- DARE $1.76
- NXTC $8.51
- Resistance Level
- DARE $1.99
- NXTC $10.56
- Average True Range (ATR)
- DARE 0.10
- NXTC 1.05
- MACD
- DARE -0.01
- NXTC -0.44
- Stochastic Oscillator
- DARE 41.44
- NXTC 0.00
About DARE Dare Bioscience Inc.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.